Exhibits ATP binding activity and MAP kinase kinase activity. Involved in negative regulation of gene expression and protein phosphorylation. Localizes to cell cortex and cytosol. Human ortholog(s) of this gene implicated in cardiofaciocutaneous syndrome 4 and small intestine adenocarcinoma. Orthologous to human MAP2K2 (mitogen-activated protein kinase kinase 2); PARTICIPATES IN the extracellular signal-regulated Raf/Mek/Erk signaling pathway; adenosine signaling pathway; ceramide signaling pathway; INTERACTS WITH 17alpha-ethynylestradiol; 17beta-estradiol 3-benzoate; 2,3,7,8-tetrachlorodibenzodioxine.
Catechin inhibits the reaction [[4-N-methyl-N-nitrosamino-1-3-pyridyl-1-butanone co-treated with Benzoapyrene] results in increased phosphorylation of MAP2K2 protein]
2-2-amino-3-methoxyphenyl-4H-1-benzopyran-4-one inhibits the reaction [Dihydrotestosterone results in increased phosphorylation of and results in increased activity of MAP2K2 protein] more ...
2-2-amino-3-methoxyphenyl-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein] more ...
Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K2 protein]
[4-N-methyl-N-nitrosamino-1-3-pyridyl-1-butanone co-treated with Benzoapyrene] results in increased phosphorylation of MAP2K2 protein, Catechin inhibits the reaction [[4-N-methyl-N-nitrosamino-1-3-pyridyl-1-butanone co-treated with Benzoapyrene] results in increased phosphorylation of MAP2K2 protein]
[U 0126 results in decreased activity of MAP2K2 protein] results in increased susceptibility to [Fluorouracil co-treated with Cisplatin], MAP2K2 protein results in decreased susceptibility to [Cisplatin co-treated with Fluorouracil]
2-2-amino-3-methoxyphenyl-4H-1-benzopyran-4-one inhibits the reaction [arsenic trioxide promotes the reaction [Tretinoin results in increased phosphorylation of and results in increased activity of MAP2K2 protein]] more ...
2-2-amino-3-methoxyphenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein] more ...
2-2-amino-3-methoxyphenyl-4H-1-benzopyran-4-one inhibits the reaction [Arsenic Trioxide promotes the reaction [Tretinoin results in increased phosphorylation of and results in increased activity of MAP2K2 protein]] more ...
AHR protein affects the reaction [Benzoapyrene affects the expression of MAP2K2 mRNA], Benzoapyrene promotes the reaction [AHR protein binds to MAP2K2 promoter]
[4-N-methyl-N-nitrosamino-1-3-pyridyl-1-butanone co-treated with Benzoapyrene] results in increased phosphorylation of MAP2K2 protein, Catechin inhibits the reaction [[4-N-methyl-N-nitrosamino-1-3-pyridyl-1-butanone co-treated with Benzoapyrene] results in increased phosphorylation of MAP2K2 protein]
2-2-amino-3-methoxyphenyl-4H-1-benzopyran-4-one inhibits the reaction [bicalutamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein] more ...
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA
[U 0126 results in decreased activity of MAP2K2 protein] results in increased susceptibility to [Fluorouracil co-treated with Cisplatin], MAP2K2 protein results in decreased susceptibility to [Cisplatin co-treated with Fluorouracil]
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA
2-2-amino-3-methoxyphenyl-4H-1-benzopyran-4-one inhibits the reaction [Arsenic Trioxide promotes the reaction [Tretinoin results in increased phosphorylation of and results in increased activity of MAP2K2 protein]] more ...
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA
Heparin inhibits the reaction [FGF1 protein results in increased phosphorylation of MAP2K2 protein], Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of MAP2K2 protein]
[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of MAP2K2 mRNA, pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of MAP2K2 mRNA]
bisindolylmaleimide I inhibits the reaction [lead acetate results in increased phosphorylation of and results in increased activity of MAP2K2 protein] more ...
Resveratrol inhibits the reaction [Dinoprost results in increased phosphorylation of MAP2K2 protein], SRT1720 inhibits the reaction [Dinoprost results in increased phosphorylation of MAP2K2 protein]
pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of MAP2K2 mRNA]
[sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K2 protein], sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K2 protein]
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
